Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Hyo Jeong Kang"
Filter
Filter
Article category
Publication year
Original Article
The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma
Jihyun An, Hyo Jeong Kang, Eunsil Yu, Han Chu Lee, Ju Hyun Shim
J Liver Cancer. 2022;22(1):40-50.   Published online March 17, 2022
DOI: https://doi.org/10.17998/jlc.2022.03.06
  • 4,151 Views
  • 124 Downloads
  • 2 Citations
AbstractAbstract PDFSupplementary Material
Background/Aim
Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of histological expression of immune checkpoint proteins in patients with resected hepatocellular carcinoma (HCC).
Methods
A total of 221 patients with HCC who underwent curative resection were included. Expression of programmed-cell death ligand-1 (PD-L1) in tumor cells (tPD-L1) and tumor infiltrating mononuclear cells (TIMCs) (iPD-L1), programmed-cell death-1 in TIMCs (iPD-1), and cytotoxic T lymphocyte antigen-4 in TIMCs (iCTLA-4) were measured immunohistochemically.
Results
Histo-positivity for iCTLA-4, iPD-1, iPD-L1, and tPD-L1 was 32.1%, 42.5%, 35.3%, and 14.9%, respectively. Multivariate logistic analyses revealed that male sex and tumor >5 cm were variables related to iCTLA-4 positivity (odds ratio [OR], 0.46 and 1.94, respectively; P<0.05). Poor differentiation was related to PD-L1 expression in both tumor cells and TIMCs (OR, 2.88 and 3.46, respectively; P<0.05). Microvascular invasion was significantly associated only with iPD-L1 (OR, 2.24; P<0.05). In time-dependent outcome analyses, expression of immune checkpoint proteins in TIMCs (i.e., iCTLA-4, iPD-1, and iPD-L1) was significantly related to longer overall survival and non-cancer-related survival (all P<0.05), but not to time-to-recurrence or cancer-specific deaths. Concurrent activation of the PD-1:PD-L1 and CTLA-4 pathways predicted improved outcomes in terms of overall survival and non-cancer related survival (P=0.06 and P=0.03, respectively).
Conclusions
Immune checkpoint proteins upregulated in TIMCs in HCC tissues have individual and additive effects in prolonging the survival of patients, specifically in terms of survival not related to cancer recurrence.

Citations

Citations to this article as recorded by  
  • The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review
    Amirhosein Sabaghian, Shahnam Shamsabadi, Saghar Momeni, Mobina Mohammadikia, Kiarash Mohebbipour, Samira Sanami, Sajjad Ahmad, Nahid Akhtar, Neeta Raj Sharma, Raja Babu Singh Kushwah, Yash Gupta, Ajit Prakash, Hamidreza Pazoki-Toroudi
    Journal of Cancer Metastasis and Treatment.2024;[Epub]     CrossRef
  • Recent Advances in Immune-based Therapy for Hepatocellular Carcinoma
    Kyung Won Park, Tae Hoon Park, Eun Ji Jang, Pil Soo Sung
    Journal of Digestive Cancer Research.2024; 12(2): 115.     CrossRef
Close layer
Review Article
Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus
Se Un Jeong, Hyo Jeong Kang
J Liver Cancer. 2022;22(1):23-29.   Published online March 17, 2022
DOI: https://doi.org/10.17998/jlc.2022.02.24
  • 8,067 Views
  • 594 Downloads
  • 6 Citations
AbstractAbstract PDF
Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest increase among all pediatric malignancies worldwide. The diagnosis of hepatoblastoma may be challenging due to the lack of a current consensus classification system. The International Pediatric Liver Tumors Consensus introduced guidelines and a consensus classification for the diagnosis of hepatoblastoma as either epithelial or mixed epithelial and mesenchymal and in the updated 5th edition of the World Health Organization Classification of Digestive System Tumors.

Citations

Citations to this article as recorded by  
  • Tumor‐associated macrophages: The key player in hepatoblastoma microenvironment and the promising therapeutic target
    Ahmad Adawy, Yoshihiro Komohara, Taizo Hibi
    Microbiology and Immunology.2024; 68(8): 249.     CrossRef
  • Hepatoblastoma: A Case Report
    Abel Ning Caballero, Kandecy Archer-Austin
    Asploro Journal of Biomedical and Clinical Case Reports.2024; 7(3): 226.     CrossRef
  • Adult Hepatoblastoma and Concomitant Hepatitis B Infection
    Alejandro Nieto Dominguez, Sarah Elizabeth Eichinger, Elza Matrova, Anas Almoghrabi
    ACG Case Reports Journal.2024; 11(9): e01491.     CrossRef
  • Metabolic and Epigenetic Mechanisms in Hepatoblastoma: Insights into Tumor Biology and Therapeutic Targets
    Yuanji Fu, Raquel Francés, Claudia Monge, Christophe Desterke, Agnès Marchio, Pascal Pineau, Yunhua Chang-Marchand, Jorge Mata-Garrido
    Genes.2024; 15(11): 1358.     CrossRef
  • Adult hepatoblastoma: making the challenging distinction from hepatocellular carcinoma
    Allison Kaye L. Pagarigan, Paulo Giovanni L. Mendoza
    Journal of Liver Cancer.2023; 23(1): 219.     CrossRef
  • Advances in Histological and Molecular Classification of Hepatocellular Carcinoma
    Joon Hyuk Choi, Swan N. Thung
    Biomedicines.2023; 11(9): 2582.     CrossRef
Close layer

JLC : Journal of Liver Cancer
TOP